Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 0.71 |
| ▸ | PGGT1B | P53609 | 14/20 | 0.71 |
| ▸ | FNTB | P49356 | 13/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31561401 | 1.00 | FNTA (0.71) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL21933140 | 1.00 | FNTA (0.71) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL20564403 | 1.00 | FNTA (0.71) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| SCHEMBL4280385 | 0.95 | FNTA (0.78) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| SCHEMBL20564402 | 0.90 | FNTA (0.61) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| SCHEMBL10018886 | 0.88 | FNTA (0.66) | FNTAPGGT1BFNTBTDP1 | |
| Trifluoroacetic Acid SCHEMBL16112378 | 0.85 | FNTA (0.91) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| SCHEMBL7608404 | 0.85 | FNTA (0.71) | FNTAPGGT1BFNTB | |
| SCHEMBL16136628 | 0.85 | FNTA (0.71) | FNTAPGGT1BFNTB | |
| SCHEMBL6775184 | 0.85 | FNTA (0.69) | FNTAPGGT1BFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2288378-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | University of Utah Research Foundation (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009148709-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20080139457-A1 | Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007035395-A9 | THERAPEUTIC COMPOSITIONS COMPRISING CHORIONIC GONADOTROPINS AND HMG COA REDUCTASE INHIBITORS | UNIV VIRGINIA COMMONWEALTH (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007035395-A2 | THERAPEUTIC COMPOSITIONS COMPRISING CHORIONIC GONADOTROPINS AND HMG COA REDUCTASE INHIBITORS | VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | RHOA, LIPG, KDR | FNTA 161/4885PGGT1B 735/4885FNTB 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.